Perioperative Durvalumab Plus FLOT Boosts EFS in Resectable Gastric/GEJ Cancer

By News Health
2 days Ago

(MedPage Today) — CHICAGO — Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115836

Author :

Publish date : 2025-06-01 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Calls for specialist unit in Northern Ireland

Survival in Unresectable Pancreatic Cancer Improved With Tumor Treating Fields

Health Groups Concerned About Cuts in Trump's Proposed 2026 Budget

At-Home Health Tests Are Here, but They Aren't Always the Best Option

Cannabis Use Rises Among U.S. Older Adults

Bivalent CAR-T Cells Via CSF Injection Show Activity in Recurrent Glioblastoma